Mucositis in the treatment of haematological malignancies

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Niscola, P ^a   Scaramucci, L ^a   Romani, C ^b   Cupelli, L ^a   Tendas, A ^a   Dentamaro, T ^a   Ales, M ^a   Giovannini, M ^a   Piccioni, D ^a   Tolu, B ^a   Perrotti, A ^a   Keefe, D ^c   de Fabritiis, P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Ospedale Oncologico A Businco   (Italy)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IDARUBICIN; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PALIFERMIN; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RITUXIMAB; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL CRAMP; ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CRYOTHERAPY; DIARRHEA; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; LOW LEVEL LASER THERAPY; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; RISK ASSESSMENT; STOMATITIS; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; RADIATION INJURY; REVIEW;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MUCOSITIS; RADIATION INJURIES;

EID: 53449093441     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn462     Document Type: Conference Paper

References (24)

1. Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic malignancies: An overview. Haematologica 2007; 92: 222-231.
2. Sonis ST, Oster G, Fuchs H et al. Oral mucosits and the clinical and economic outcomes of hematopoiefic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
3. Niscola P, Arcuri E, Giovannini M et al. Pain syndromes in haematological malignancies: An overview. Hematol J 2004; 5: 293-303.
4. Niscola P, Romani C, Cartoni C et al. Epidemiology of pain in hospital haematological setting: An Italian survey. Leuk Res 2008; 32: 197-198.
5. Niscola P, Romani C, Scaramucci L et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant 2008; 41: 757-764.
6. Sonis ST, Elting LS, Keefe D et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (Suppl 9): 1995-2025.
7. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucosits. Cancer 2007; 109: 820-831.
8. Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007; 15: 483-490.
9. Keefe DM. Gastrointestinal mucositis: A new biological model. Support Care Cancer 2004; 12: 6-9.
10. Keefe DM. Intestinal mucositis: Mechanisms and management. Curr Opin Oncol 2007; 19: 323-327.
11. Bowen JM, Gibson RJ, Cummins AG, Keefe DM, Intestinal mucositis: The role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006; 14: 713-731.
12. Miaskowski C. Biology of mucosal pain. J Natl Cancer Inst Monogr 2001; 29: 37-40.
13. Quinn B, Potting CM, Stone R et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patents. Eur J Cancer 2008; 44: 61-72.
14. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100 (Suppl 9): 2026-2046.
15. Kuskonmaz B, Yalcin S, Kucukbayrak O et al. The effect of glutamine supplementation on hematopoietic stem cell transplant outcome in children: A case-control study. Pediatr Transplant 2008; 12: 47-51.
16. Aquino VM, Harvey AR, Garvin JH et al. A double-blind randomized placebocontrolled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantabon: A pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2005; 36: 611-616.
17. Sironi M, Milanese C, Vecchi A et al. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 1997; 27: 118-122.
18. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study. Br J Haematol 2000; 110: 300-307.
19. Worthington HV, Clarkson JE, Eden OB. Interventons for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2007; 4: CD000978.
20. Schubert MM, Eduardo FP, Guthrie KA et al. A phase III randomized double-blind placebo-Gontrolled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantabon. Support Care Cancer 2007; 15: 1145-1154.
21. Posner MR, Haddad RI. Novel agents for the treatment of mucositis. J Support Oncol 2007; 5 (9, Suppl 4): 33-39.
22. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
23. Stiff PJ, Emmanouilides C, Bensinger WI et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietc stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186-5193.
24. Nasilowska-Adamska B, Rzepecki P, Manko J et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-988.